帕金森病第一年高与低抗帕金森病药物剂量与死亡率风险：一项真实世界研究。
Risk for Mortality in High versus Low Antiparkinsonian Therapy Dose During the First Year of Parkinson's Disease: A Real-World Study.
机构信息
Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Ha'Mered 27, 6812509, Tel Aviv, Israel.
AbbVie Inc., North Chicago, IL, USA.
出版信息
Adv Ther. 2024 Aug;41(8):3419-3425. doi: 10.1007/s12325-024-02924-8. Epub 2024 Jul 8.
INTRODUCTION
Early, simple predictors for long-term survival in Parkinson's disease (PD) may help identify patients at elevated risk and are crucial for more personalized treatment.
METHODS
This large, retrospective study examined whether higher levodopa equivalent daily dose (LEDD) a year after diagnosis predicts long-term survival.
RESULTS
Mortality risk was increased among 292 patients receiving ≥ 600 mg LEDD versus 2233 patients receiving < 600 mg LEDD (hazard ratio 1.5; 95% confidence interval 1.3-1.7), particularly among patients aged < 75 years (1.8; 1.4-2.4).
CONCLUSION
In PD, higher LEDD can be an early risk marker of increased mortality, probably because it reflects more severe disease.
简介
帕金森病（PD）长期生存的早期简单预测因素可能有助于识别风险较高的患者，对更个性化的治疗至关重要。
方法
这项大型回顾性研究探讨了诊断后一年左旋多巴等效每日剂量（LEDD）较高是否预测长期生存。
结果
与 2233 名接受<600mg LEDD 的患者相比，292 名接受≥600mg LEDD 的患者的死亡风险增加（风险比 1.5；95%置信区间 1.3-1.7），尤其是在<75 岁的患者中（1.8；1.4-2.4）。
结论
在 PD 中，较高的 LEDD 可能是死亡率增加的早期风险标志物，可能因为它反映了更严重的疾病。
Zotero 插件